HRP20010367A2 - Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress - Google Patents

Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress Download PDF

Info

Publication number
HRP20010367A2
HRP20010367A2 HR20010367A HRP20010367A HRP20010367A2 HR P20010367 A2 HRP20010367 A2 HR P20010367A2 HR 20010367 A HR20010367 A HR 20010367A HR P20010367 A HRP20010367 A HR P20010367A HR P20010367 A2 HRP20010367 A2 HR P20010367A2
Authority
HR
Croatia
Prior art keywords
pbr
substance
preparation
strain
use according
Prior art date
Application number
HR20010367A
Other languages
English (en)
Croatian (hr)
Inventor
Pierre Casellas
Jena-Marie Derocq
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HRP20010367A2 publication Critical patent/HRP20010367A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
HR20010367A 1998-11-17 1999-11-10 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress HRP20010367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814387A FR2785803B1 (fr) 1998-11-17 1998-11-17 Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
PCT/FR1999/002761 WO2000028947A2 (fr) 1998-11-17 1999-11-10 Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes

Publications (1)

Publication Number Publication Date
HRP20010367A2 true HRP20010367A2 (en) 2002-06-30

Family

ID=9532791

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010367A HRP20010367A2 (en) 1998-11-17 1999-11-10 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress

Country Status (17)

Country Link
US (2) US6767533B1 (de)
EP (1) EP1131039B1 (de)
JP (1) JP2002529486A (de)
KR (1) KR20010089475A (de)
AT (1) ATE298230T1 (de)
AU (1) AU764786B2 (de)
CA (1) CA2349919A1 (de)
CY (1) CY1105144T1 (de)
DE (1) DE69925928T2 (de)
DK (1) DK1131039T3 (de)
ES (1) ES2244246T3 (de)
FR (1) FR2785803B1 (de)
HR (1) HRP20010367A2 (de)
HU (1) HUP0105058A2 (de)
PT (1) PT1131039E (de)
SI (1) SI1131039T1 (de)
WO (1) WO2000028947A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300947T1 (de) * 1998-12-18 2005-08-15 Scios Inc Behandlung von erkrankungen mit zystenbildung
EP2359831A3 (de) * 1999-04-30 2012-02-01 The Regents of the University of Michigan Therapeutische Anwendungen proapoptotischer Benzodiazepine
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
BR0314595A (pt) 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006067327A2 (fr) * 2004-12-20 2006-06-29 L'oreal Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches
FR2879451B1 (fr) * 2004-12-20 2007-05-04 Oreal Utilisation de ligands du recepteur des benzodiazepines pour lutter contre les signes du vieillissement
EP1830796A2 (de) * 2004-12-20 2007-09-12 L'Oréal Verwendung von benzodiazepin-rezeptor-liganden zur bekämpfung der zeichen von alterung
FR2879450B1 (fr) * 2004-12-20 2007-02-09 Oreal Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
WO2007053193A2 (en) * 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
EP1948191B1 (de) 2005-11-01 2013-01-16 The Regents of the University of Michigan Neuartige 1,4-benzodiazepin-2,5-dione mit therapeutischen eigenschaften
KR20070058292A (ko) * 2005-12-02 2007-06-08 엘지전자 주식회사 기록매체, 기록매체 기록재생 방법 및 장치와 기록매체클로징 방법
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2418206A3 (de) 2006-06-09 2012-06-27 The Regents of the University of Michigan Benzodiazepin-derivate zur behandlung von autoimmunerkrankungen
WO2008001357A2 (en) * 2006-06-26 2008-01-03 Technion Research & Development Foundation Ltd. Methods and kits for diagnosing cancer
CA2680017C (en) 2007-03-09 2013-11-12 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
NZ583265A (en) * 2007-08-31 2012-01-12 Archimedes Dev Ltd Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate
EP2200977B1 (de) 2007-09-14 2016-11-09 The Regents of the University of Michigan F1f0-atpase-inhibitoren und damit in zusammenhang stehende verfahren
MX2010004857A (es) 2007-11-06 2010-07-28 Univ Michigan Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel.
EP2352724B1 (de) 2008-09-11 2015-04-22 The Regents of the University of Michigan Arylguanidine-f1f0-aptase inhibitoren und deren therapeutischen verwendung
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CN102753544A (zh) 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1，4-苯并二氮杂*-2，5-二酮和相关化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5279082A (en) * 1975-12-25 1977-07-02 Green Cross Corp:The Preparation of anti-tumor compound
JPS5473195A (en) * 1977-11-22 1979-06-12 Takeda Chem Ind Ltd Preparation of tomaymycins
JPS56121495A (en) * 1980-02-29 1981-09-24 Kyowa Hakko Kogyo Co Ltd Preparation of benzodiazepine derivative
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
JP3567990B2 (ja) * 1992-07-28 2004-09-22 ザ、プロクター、エンド、ギャンブル、カンパニー 架橋陽イオン重合体とアルコキシ化エーテルとを含有する局所用途用医薬組成物
EP2359831A3 (de) * 1999-04-30 2012-02-01 The Regents of the University of Michigan Therapeutische Anwendungen proapoptotischer Benzodiazepine

Also Published As

Publication number Publication date
FR2785803B1 (fr) 2005-03-25
ATE298230T1 (de) 2005-07-15
US20050090489A1 (en) 2005-04-28
AU1166100A (en) 2000-06-05
DE69925928T2 (de) 2006-08-17
JP2002529486A (ja) 2002-09-10
HUP0105058A2 (hu) 2002-05-29
AU764786B2 (en) 2003-08-28
DK1131039T3 (da) 2005-10-17
EP1131039B1 (de) 2005-06-22
HK1037966A1 (en) 2002-03-01
DE69925928D1 (de) 2005-07-28
CA2349919A1 (en) 2000-05-25
CY1105144T1 (el) 2010-03-03
ES2244246T3 (es) 2005-12-01
WO2000028947A2 (fr) 2000-05-25
PT1131039E (pt) 2005-11-30
FR2785803A1 (fr) 2000-05-19
SI1131039T1 (en) 2005-10-31
KR20010089475A (ko) 2001-10-06
WO2000028947A3 (fr) 2000-08-03
US6767533B1 (en) 2004-07-27
EP1131039A2 (de) 2001-09-12

Similar Documents

Publication Publication Date Title
HRP20010367A2 (en) Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
US6562355B1 (en) Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin
CN1933805B (zh) 减少因衰老而出现的皱纹的化妆品或皮肤用药
US11759544B2 (en) Therapeutic compositions for enhanced healing of wounds and scars
US8722108B2 (en) Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression
AU2022379566B2 (en) Biosurfactant formulations for use in skincare and wound treatment
JP2003063984A (ja) Ｎ−アシルアミノアミドファミリーのエラスターゼ阻害剤と少なくとも１種の抗真菌剤又は少なくとも１種の抗菌剤の組み合わせを含む化粧品用又は皮膚用組成物
KR20230048515A (ko) 천연 스킨케어 조성물
WO2023192979A2 (en) Compositions and methods for promoting hair growth
US6264962B1 (en) Use of cinnamic acid or of at least one of its derivatives in a cosmetic composition
AU619399B2 (en) Cosmetic composition containing compounds obtained by the culture of cells, especially fibroblasts or keratinocytes
WO2023196763A1 (en) Therapeutic compositions for enhanced healing of wounds and scars
HK1037966B (en) Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
CA3107300C (en) Therapeutic compositions for enhanced healing of wounds and scars
KR20070031472A (ko) 피부 스트레스 치료를 위한 벤조디아제핀 말초 수용체와결합하는 물질의 용도
CN119185094A (zh) 环二肽的抗炎舒缓功效及其应用
BR112015017934B1 (pt) Uso de um extrato de lactobacillus delbrueckii, processo de elicitação de células vegetais e de preparação de uma composição, composições, composição cosmética e usos da composição cosmética
EP0465663A1 (de) Dermatologische zubereitung
CN119112699A (zh) 环二肽的抗衰老功效及其应用
HK1162968A (en) Anti-wrinkle cosmetic skin composition containing leontopodic acid as an active ingredient

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

ODRP Renewal fee for the maintenance of a patent

Payment date: 20061005

Year of fee payment: 8

ODBI Application refused